Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has assisted in connection with Samhällsbyggnadsbolaget’s listing on Nasdaq Stockholm
Mandate

Vinge has assisted in connection with Samhällsbyggnadsbolaget’s listing on Nasdaq Stockholm

September 26, 2019 Capital Markets and Public M&A

Vinge has assisted with counselling on securities law and transaction execution in connection with Samhällsbyggnadsbolaget i Norden AB (publ)’s list change of their B‑ and D‑shares from Nasdaq First North Premier Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 18 September 2019 and the trading on Nasdaq Stockholm commenced 20 September 2019.

The company’s strategy is to own, manage and develop community service properties throughout the Nordic region and rental apartments in growth regions in Sweden. As of 30 June 2019, the
property portfolio consisted of 790 properties with a reported amount for investment properties totalling SEK 30.3 billion.

Vinge’s team has primarily consisted of Jesper Schönbeck, Malte Hedlund, Boris Kotur, Anders Sundin Lundberg and Nils Fredrik Dehlin. Maria Schultzberg, Victor Ericsson and Henrik Wastenson advised on tax issues.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025